metaPreg - Albendazole during pregnancy

Albendazole updated on 01-29-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.71 [0.50, 5.82]	0%	2 studies	13	104	not evaluable	ROB	-
Congenital heart defects	-	-	0 study					-
Nervous system anomalies	-	-	0 study					-
Limb defects	-	-	0 study					-
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	-	-	0 study					-
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Infant asthma	1.58 [1.13, 2.21]	-	1 study		583	not evaluable	ROB	2.54 [1.51; .]
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.41 [0.55, 3.60]	0%	2 studies	22	118	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study